Key result
Only ~45% of surveyed clinicians routinely perform perioperative troponin surveillance during high-risk non-cardiac surgery.
Why the study?
Guidelines recommend perioperative high-sensitivity cardiac troponin surveillance in selected higher-risk patients undergoing non-cardiac surgery, yet real-world implementation, adherence to sampling timepoints, perceived barriers, and dabigatran use for PMI/MINS were uncertain.
Cross-Sectional (n=261)
Yes
Real-world perioperative troponin surveillance in higher cardiac-risk patients undergoing non-cardiac surgery is heterogeneous, with under half of surveyed anaesthesiologists monitoring routinely and major barriers cited as follow-up issues, financial constraints, and perceived lack of therapeutic impact.
Answers are grounded in this paper and cite their sources.
Low adherence to troponin monitoring guidelines may leave perioperative injury undetected; leaves open effective implementation strategies for high-risk non-cardiac surgery.
Introduction Perioperative myocardial infarction/injury (PMI) or myocardial injury after non-cardiac surgery (MINS) is common, mostly clinically silent and associated with increased mortality. Guidelines recommend perioperative high-sensitivity cardiac troponin surveillance in selected higher-risk patients, yet real-world implementation is uncertain. We assessed current troponin monitoring practices, adherence to guideline-recommended sampling timepoints, perceived barriers and reported use of dabigatran for PMI/MINS. Methods We conducted an anonymous, international, web-based survey of clinicians working in anaesthesia between May 2024 and March 2025. This analysis focused on a supplemental four-question module addressing frequency of perioperative troponin monitoring in higher cardiac-risk patients undergoing non-cardiac surgery, sampling patterns, reasons for not monitoring and institutional dabigatran use. Respondents were described overall and compared between European and non-European respondents in an exploratory analysis. Results Of 261 respondents from at least 26 countries, fewer than half monitored troponin routinely (22% almost always, 23% usually), 32% monitored sometimes, 17% rarely and 7% never. Among those monitoring at least rarely ( n = 244), 55% reported predefined sampling consistent with 2022 ESC recommendations, 10% used alternative routine timepoints and 31% measured troponin only in symptomatic patients. Of the options provided, follow-up issues (33%), financial constraints (29%), and a perceived minimal/no therapeutic impact (24%) were indicated as reasons for not performing routine monitoring. Dabigatran was rarely used: 5% reported routine use and 17% use in select cases; 53% were unaware of dabigatran use for PMI/MINS. Conclusions Perioperative troponin surveillance in higher cardiac-risk patients is heterogeneous, with only about half of monitoring clinicians following guideline-recommended sampling timepoints and substantial reliance on symptom-triggered testing. When troponin was not monitored, common reasons cited were logistical and financial barriers and uncertainty about downstream management. Pragmatic, resourced pathways linking troponin surveillance to structured interpretation, follow-up and treatment decisions may improve consistency. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Harms et al. (2026) conducted a cross-sectional in Perioperative myocardial infarction/injury (PMI) or myocardial injury after non-cardiac surgery (MINS) (n=261). Perioperative high-sensitivity cardiac troponin surveillance vs. European vs. non-European respondents was evaluated on Frequency of routine perioperative troponin monitoring in higher cardiac-risk patients undergoing non-cardiac surgery. Perioperative troponin surveillance in higher-risk non-cardiac surgery was routinely performed by fewer than half of surveyed clinicians, with 55% following ESC sampling timepoints.
Synapse has enriched 10 related papers. Consider them for comparative context: